Legal entity
Novo Nordisk is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. The 66-day window averages about 0.3 stories each week. The busiest single day carried 2. The clearest coverage concentration is court-decisions: 2 of 3 stories, with the rest divided among 1 other category.
Last mentioned: Sep 24, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 67 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Novo Nordisk is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. The 66-day window averages about 0.3 stories each week. The busiest single day carried 2. The clearest coverage concentration is court-decisions: 2 of 3 stories, with the rest divided among 1 other category. The 7 average consequence score is above the beat benchmark of 5.9 in the same window. They are less corroborated than the beat average, carrying 2.3 original sources each against 2.5 for the same window. This profile follows 3 Legal stories mentioning GLP-1 Receptor Agonists across the period from July 21, 2026 to September 24, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 649 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering GLP-1 Receptor Agonists. Shared-story counts are live from our verified record — not editorial picks.
Civil lawsuit against Novo Nordisk reported
The Wall Street Journal reported a civil lawsuit filed against Novo Nordisk by patients who developed NAION after taking Wegovy or Ozempic; similar cases against Eli Lilly are pending.
Lawsuit Filed
Novo Nordisk sues Eli Lilly in the U.S. District Court for the District of New Jersey, alleging false advertising and unfair competition under the Lanham Act.
FDA Approves Wegovy 7.2 mg
Novo Nordisk receives U.S. approval for a higher-dose semaglutide injection for obesity, backed by the STEP UP trial showing 19% average weight loss.
AAO issues statement on GLP-1s and vision loss
The American Academy of Ophthalmology released a news release urging clinicians and patients to make informed choices about GLP-1 use after studies linked the drugs to vision loss.
First NAION lawsuits filed against GLP-1 makers in New Jersey
Patients begin filing lawsuits alleging that GLP-1 drugs such as Ozempic, Wegovy, and Zepbound caused permanent vision loss and that manufacturers failed to warn about the risk.
Boston medical center issues safety alert
Researchers at a Boston medical facility sent a safety alert flagging a possible connection between GLP-1 medications and NAION.
Nearly 100 NAION lawsuits against Novo Nordisk and Eli Lilly test pharmaceutical failure-to-warn liability. Mixed epidemiological evidence and diabetes-related blindness risk create a dense causation battleground for mass tort litigators.
Mass tort litigation against Novo Nordisk and Eli Lilly is escalating, with nearly 1,000 cases in New Jersey alone alleging the companies failed to warn patients about NAION risk.
Novo Nordisk alleges Lanham Act violations; case tests whether outdated comparisons in DTC ads constitute false advertising, with potential precedent for pharma.
Source: rttnews.com · finanznachrichten.de
GLP-1 Receptor Agonists is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
